Dr David Bloom | Professor of Economics and Demography
Harvard T.H. Chan School of Public Health

Dr David Bloom, Professor of Economics and Demography, Harvard T.H. Chan School of Public Health

David Bloom is Clarence James Gamble Professor of Economics and Demography at the Harvard T.H. Chan School of Public Health and Director of Harvard University’s NIH/NIA-funded Program on the Global Demography of Aging. Bloom received a B.S. in Industrial and Labor Relations from Cornell University in 1976, an M.A. in Economics from Princeton University in 1978, and a Ph.D. in Economics and Demography from Princeton University in 1981. Bloom's current research focuses heavily on the interplay of health, demographics, and economic growth and development, and also on the value of vaccination. Bloom has taught numerous courses on labor, health, and population and on statistics and econometrics. He has also published more than 450 articles, book chapters, and books, and is a founding co-editor of the Journal of the Economics of Ageing. In April 2005, Bloom was elected Fellow of the American Academy of Arts and Sciences. In 2015, he was named an Andrew Carnegie Fellow of the Carnegie Corporation of New York.


DC Pre-congress WS day April 2 @ 2:00

Workshop C: Market access & regulatory challenges in vaccines

The market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Recommendation from the ACIP is an important step towards funding and getting a vaccine to market. 

Join us at the workshop to understand the key components of the ACIPs decisions to recommend and fund and how industry can facilitate this process. Learn how to cope with the obstacles to make sure we get optimal value for our vaccines and discover the pit falls to avoid when launching a new vaccine.

Recommendations and Funding: What are the key components to the ACIPs evaluation of vaccines?

The Value of Vaccination 

Accelerating Access to Vaccines: A manufacturer’s perspective​

back to speakers